John F Wheeler

US Patent:

8394378, Mar 12, 2013

Filed:

Sep 26, 2011

Appl. No.:

13/245299

Inventors:

John Kehoe - Radnor PA, US
Jennifer Lee Gardiner - Seattle WA, US
Tatiana Ort - Radnor PA, US
Kristen Picha - Radnor PA, US
Mary Ryan - Radnor PA, US
John Wheeler - Radnor PA, US

Assignee:

Janssen Biotech, Inc. - Horsham PA

International Classification:

A61K 39/00
C07K 16/00
C07K 16/46

US Classification:

4241331, 5303871, 5303873, 53038825

Abstract:

The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.

US Patent:

20100021477, Jan 28, 2010

Filed:

Aug 25, 2009

Appl. No.:

12/546850

Inventors:

Ping Tsui - Berwyn PA, US
Lei Shi - Radnor PA, US
Jin Lu - Radnor PA, US
John Wheeler - Radnor PA, US
Brian Whitaker - Radnor PA, US
Lionella Borozdina-Birch - San Diego CA, US
Juan C. Almagro - Radnor PA, US
Bernard Amegadzie - Radnor PA, US
Mark Tornetta - Radnor PA, US
Ramachandra Reddy - Radnor PA, US
David M. Knight - Radnor PA, US
Jinquan Luo - Radnor PA, US
Raymond W. Sweet - Radnor PA, US
Qiang Chen - San Diego CA, US

International Classification:

A61K 39/40
C12N 15/63
C12N 1/21
C07K 14/195
C07K 16/12
C40B 40/02
C40B 30/04

US Classification:

4241641, 4353201, 4352523, 530350, 5303871, 506 14, 506 9

Abstract:

Described and claimed herein are combinatorial synthetic Fab libraries displayed on a phage pIX protein. The libraries were built on scaffolds representing the most frequently used genes in human antibodies, which were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific and high-affinity Fabs were isolated. By a process called in-line maturation the affinity of some antibodies was improved up to one hundred-fold yielding low pM binders suitable for in vivo use. This work thus demonstrates the feasibility of displaying complex Fab libraries as pIX-fusion proteins for antibody discovery and lays the foundations for studies on the structure-function relationship of antibodies.

US Patent:

20110318353, Dec 29, 2011

Filed:

Mar 30, 2011

Appl. No.:

13/075241

Inventors:

Juan Carlos Almagro - Radnor PA, US
Patrick Branigan - Radnor PA, US
Colleen Kane - Radnor PA, US
William Strohl - Radnor PA, US
Susann Taudte - Radnor PA, US
Mark Tornetta - Radnor PA, US
John Wheeler - Radnor PA, US

International Classification:

A61K 39/395
C12N 15/13
C12N 15/63
A61P 29/00
C12N 1/21
C12P 21/00
C12P 21/02
A61P 11/06
C07K 16/24
C12N 5/10

US Classification:

4241391, 5303879, 5303892, 536 2353, 4353201, 435331, 435335, 4352523, 43525233, 435 696, 4241581, 5303873

Abstract:

The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).

US Patent:

20220193133, Jun 23, 2022

Filed:

Dec 17, 2021

Appl. No.:

17/554062

Inventors:

- Philadelphia PA, US
Michael Francis NASO - Swarthmore PA, US
Luis Ghira BORGES - Philadelphia PA, US
John WHEELER - Downingtown PA, US
Andrew DEVANEY - Warwick NY, US

Assignee:

CENTURY THERAPEUTICS, INC. - Philadelphia PA

International Classification:

A61K 35/17
C12N 5/0783

Abstract:

The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have adaptable receptor specificity (arCARs). Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.